Medicus Pharma Ltd. (MDCX) Key Metrics
MDCX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.7M
- Enterprise value
- $17.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 12.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.30
MDCX key metrics, 2010–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMDCX returns How much profit the business earns on the capital it uses.
MDCX financial health Debt, liquidity and how easily interest is covered.
MDCX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MDCX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MDCX price vs earnings per share
MDCX key metrics
2010–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2017 | 2016 | 2015 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $26.4M | — | — | — | — | — | — | — | — |
| Enterprise value | $21.7M | — | — | — | — | — | — | — | — |
| Earnings yield | −95.9% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −86.1% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $76.50 | $121.50 | — | — | — | — | — | — | — |
| Per share | |||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | −$73.38 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$65.89 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$65.89 | — | — | — | — | — | — | — | — |
| Cash per share | $25.18 | — | — | — | — | — | — | — | — |
| Book value per share | −$0.20 | — | — | — | — | — | — | — | — |
| Tangible book value per share | −$0.20 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | $11.56 | — | — | — | — | — | — | — | — |
| Shares outstanding | 346K | — | — | — | — | — | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | — | −525.4% | — | — | — | — | — | — | — |
| Return on invested capital (ROIC) | — | — | — | — | — | — | — | — | −133.3% |
| Return on assets (ROA) | −323.0% | −295.9% | −488.6% | −937.2% | — | −342.2% | — | — | −23.1% |
| Return on tangible assets | −252.1% | −197.6% | −280.8% | −598.8% | — | −342.2% | — | — | −23.1% |
| Free cash flow margin | — | — | — | — | — | — | — | — | −9.5% |
| Financial health | |||||||||
| Total debt | $4.0M | $322,268 | — | $1.5M | $667,931 | — | $3,850 | $750 | $2.3M |
| Cash & short-term investments | $8.7M | $4.2M | $1.7M | $267,652 | $78,514 | $40,583 | — | — | $5,410 |
| Net debt | −$4.7M | −$3.8M | −$1.7M | $1.3M | $589,417 | −$40,583 | $3,850 | $750 | $2.3M |
| Debt / equity | — | 0.10 | — | — | — | — | — | — | — |
| Debt / assets | 0.40 | 0.06 | — | 5.42 | 8.51 | — | — | — | 0.77 |
| Net debt / EBITDA | — | — | −0.95 | — | — | — | — | — | — |
| Current ratio | 1.00 | 2.33 | 2.42 | 0.02 | 0.01 | 12.55 | — | — | 0.68 |
| Quick ratio | 1.00 | 2.33 | 2.42 | 0.02 | 0.01 | 12.55 | — | — | 0.44 |
| Interest coverage | -129.9 | -35.2 | -7.9 | -1.9 | -12.5 | — | — | — | — |
| Working capital | −$47,418 | $3.1M | $1.1M | −$12.2M | −$10.5M | $37,349 | — | — | −$1.4M |
| Invested capital | −$4.8M | −$707,351 | −$607,890 | −$10.9M | −$9.9M | −$103,234 | — | — | $299,717 |
| Tangible asset value | $37,311 | $3.1M | $1.1M | −$12.2M | −$10.5M | −$62,651 | — | — | −$2.0M |
| Net current asset value | −$133,422 | $2.9M | $1.1M | −$12.2M | −$10.5M | −$62,651 | — | — | −$2.0M |
| Graham net-net per share | −$3.82 | — | — | — | — | — | — | — | — |
| Capital allocation | |||||||||
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $0 | — |
| Capex / revenue | — | — | — | — | — | — | — | — | 0.0% |
| Capex / depreciation | — | — | 0.00 | — | — | — | — | — | 0.00 |
| SG&A / revenue | — | — | — | — | — | — | — | — | 14.6% |
| Efficiency | |||||||||
| Days sales outstanding | — | — | — | — | — | — | — | — | 53.7 |
| Days of inventory on hand | — | — | — | — | — | — | — | — | 34.2 |
| Days payables outstanding | — | — | — | — | — | — | — | — | 87.0 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | 0.9 |
| Receivables turnover | — | — | — | — | — | — | — | — | 6.80 |
| Payables turnover | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 4.19 |
| Inventory turnover | — | — | — | — | — | — | — | — | 10.66 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 4.21 |
| Average receivables | — | — | — | — | — | — | — | — | $1.9M |
| Average payables | $2.4M | $747,727 | $210,842 | — | — | $4,284 | $4,000 | $1.3M | $2.7M |
| Average inventory | — | — | — | — | — | — | — | — | $1.1M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | 0.0% |
Computed from MDCX's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MDCX valuation and financial ratios
It ended the year with $4.0 million of debt and $8.7 million in cash and short-term investments, a net cash position of $4.7 million.
See the MDCX income statement, the MDCX chart for price history, or the MDCX stock overview for the latest quote and news.
MDCX key metrics FAQ
How much debt does Medicus Pharma have?
Medicus Pharma had total debt of $4.0 million at the end of fiscal 2025 and more cash than debt.
What is Medicus Pharma's free cash flow yield?
Medicus Pharma generated -$22.8 million of free cash flow in fiscal 2025, a free cash flow yield of −86.1% on its market value at year-end ($26.4 million).
What is Medicus Pharma's current ratio?
Medicus Pharma's current ratio was 1.00 at the end of fiscal 2025: current assets were 1.00 times current liabilities.